Inspection Record

Delta Pharma Inc. — FDA 483 Findings

US FDAInspected 2018-06-08Published 2024-01-17 9 findingsTraining and personnelAseptic processing and sterility assuranceEquipment and facilityLaboratory and QC controlsProcess validationLabeling and packagingStability and storageDocumentation and records

Inspectors Zada L. Giles · Marvin D. JonesThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Training and personnel

Clothing of personnel engaged in the processing of drug products is not appropriate for the duties they perform.

2Aseptic processing and sterility assurance

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include validation of the sterilization process.

3Equipment and facility

Routine calibration of equipment is not performed according to a written program designed to assure proper performance.

4Laboratory and QC controls

Testing and release of drug product for distribution do ·not include appropriate laboratory determination of satisfactory conformance to the final specifications prior to release.

5Process validation

Time limits are not established when appropriate for the completion of each production phase to assure the quality of the drug product.

6Labeling and packaging

The labels of your outsourcing facility's drug products does not include information required bysections 503B(a) (10)(A) and (B).

7Stability and storage

There is no written testing program designed to assess the stability characteristics of drug products.

8Aseptic processing and sterility assurance

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

9Documentation and records

Batch production and control records do not include complete information relating to the production and control of each batch.

About this record

Extracted automatically from the document US FDA published on 2024-01-17. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Other records for this company

Delta Pharma Inc. company profile — full history US FDA documents, 2024 Go to Findings search